Condition
Macular Edema, Diabetic
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Terminated1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT02788877Phase 4UnknownPrimary
Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)
NCT01994291Phase 2TerminatedPrimary
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
Showing all 2 trials